Budget impact analysis of thrombolysis for stroke in Spain: A discrete event simulation model

Value in Health

Volumn 13, Issue 1, 2010, Pages 69-76

  Mar, Javier ^a   Arrospide, Arantzazu ^a   Comas, Mercè ^b,c  

^a Hospital Alto Deba   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

Budget impact analysis; Pharmaceuticals; Simulation models; Stroke

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; COST CONTROL; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SPAIN; STROKE;

EID: 72949114081     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00655.x     Document Type: Article

References (36)

1. Sarti C, Rastenyte D, Cepaitis Z, Tuomilehto J. International trends in mortality from stroke, 1968 to 1994. Stroke 2000 31 : 1588 1601.
2. Hankey GJ. Stroke Treatment and Prevention: An Evidence-Based Approach. New York : Cambridge University Press, 2005.
3. Arrazola A, Begiristain JM, Mar J. Atención hospitalaria a la enfermedad cerebrovascular aguda y situación de los pacientes a los 12 meses. Rev Neurol 2005 40 : 326 330.
4. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999 340 : 1781 1787.
5. Mar J, Begiristain JM, Arrazola A. Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc Dis 2005 20 : 193 200.
6. Fagan SC, Morgenstern LB, Pettita A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998 50 : 883 890.
7. Sinclair SE, Frighetto L, Loewen PS, et al. Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke. A Canadian healthcare perspective. Pharmacoeconomics 2001 19 : 927 936.
8. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. JAMA 1996 276 : 1172 1177.
9. Baltussen R, Leidl R, Ament A. Real world designs in economic evaluations. Bridging the gap between clinical research and policy-making. Pharmacoeconomics 1999 16 : 449 458.
10. Mauskopf J, Earnshaw S, Mullins CD. Budget impact analysis: review of the state of art. Exp Rev Pharmacoeconom Res 2005 5 : 65 79.
11. Groppelli AA, Nickbackht E. Barron's Finance (4th ed.). New York : Barron's Educational Series, Inc., 2000.
12. Mar J, Sainz-Ezkerra M, Miranda-Serrano E. Calculation of prevalence through Markov models. Application to prevalence-based economic evaluation of thrombolysis for stroke. Med Decis Making 2008 28 : 481 490.
13. Rothman KJ, Greenland S. Measures of disease frequency. In : Rothman KJ, Greenland S, eds. Modern Epidemiology. Philadelphia, PA : Lippincott, Williams and Wilkins, 1998.
14. Rothwell PM. The high cost of not funding stroke research: a comparison with heart disease and cancer. Lancet 2001 357 : 1612 1616.
15. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. London : NICE, 2004. Available from: http://www.nice.org. uk/niceMedia/pdfTAP-655-methods.pdf [Accessed September 9, 2009 J. Prevalence-based economic evaluation. Value Health 1998 1 : 251 259.
16. Orlewska D, Mierzejewski P. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health 2004 7 : 1 10.
17. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2003 19 : 609 621.
18. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices - budget impact analysis. Value Health 2007 10 : 336 347.
19. Sonnenberg FA, Beck R. Markov models in medical decision making: a practical guide. Med Decis Making 1993 13 : 322 338.
20. Briggs AH, Goeree R, Blackhouse G, O'Brien B. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002 22 : 290 308.
21. Stahl JE, Furie KL, Gleason S, Gazelle GS. Stroke: effect of implementing an evaluation and treatment protocol compliant with NINDS recommendations. Radiology 2003 228 : 659 668.
22. Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005 23 : 323 332.
23. Comas M, Castells X, Hoffmeister L, et al. Discrete-event simulation applied to the analysis of waiting lists. Evaluation of a prioritization system for cataract surgery. Value Health 2008 11 : 1203 1213 Epub ahead of print B, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics 2005 23 (Suppl. 1 S17 33.
24. Kelton WD, Sadowski RP, Sturrock DT. Simulation with ARENA. New York : McGraw Hill, 2007.
25. Roman R, Comas M, Hoffmeister L, Castells X. Determining the lifetime density function using a continuous approach. J Epidemiol Community Health 2007 61 : 923 925.
26. Briggs A, Ades AE, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Med Decis Making 2003 23 : 341 350.
27. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md State Med J 1965 14 : 61 5.
28. Bonita R, Solomon N, Broad JB. Prevalence of stroke and stroke-related disability: estimates from the Auckland Stroke Studies. Stroke 1997 28 : 1898 1902.
29. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995 333 : 1581 1587.
30. Hilden J. Budget impact analysis and its rational basis. Med Decis Making 2008 28 : 461 462.
31. Mar J, Sainz-Ezkerra M, Moler-Cuiral JA. Calculation of prevalence estimates through differential equations: application to stroke-related disability. Neuroepidemiology 2008 31 : 57 66.
32. Clarke PM, Gray AM, Briggs A, et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005 48 : 868 877.
33. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. New York : Oxford University Press, 1999.
34. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus. Lancet 2005 366 : 2112 2117.
35. Whiteley W, Lindley R, Wardlaw J, et al. Third international stroke trial. Int J Stroke 2006 1 : 172 176.
36. Belvis R, Cocho D, Marti-Fabregas J, et al. Benefits of a prehospital stroke code system. Feasibility and efficacy in the first year clinical practice in Barcelona. Cerebrovasc Dis 2005 19 : 96 101.